Form 4: Mirum Director Exercises Options, Sells Shares

Mirum Pharmaceuticals Director Saira Ramasastry exercised stock options and sold an equal number of shares on January 15, 2026, under a pre-arranged 10b5-1 plan.

Summary

• Director Saira Ramasastry exercised 2,000 stock options for Mirum Pharmaceuticals common stock at an exercise price of $23.51 per share.
• Concurrently, Ramasastry sold 2,000 shares of common stock at a price of $90.99 per share.
• These transactions occurred on January 15, 2026, and were executed under a Rule 10b5-1 trading plan adopted on September 18, 2025.
• Following these transactions, Ramasastry's direct beneficial ownership of common stock is 0 shares, but still holds 8,000 unexercised stock options.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale under a 10b5-1 plan, which is generally neutral. The director realized a significant gain, which is positive for the individual, but the reduction in direct share ownership could be seen as slightly negative by some investors, though mitigated by the pre-planned nature and remaining option holdings.

Positives

• The sale was executed at a significantly higher price ($90.99) than the exercise price ($23.51), indicating a substantial gain for the director.
• The transaction was pre-planned under a Rule 10b5-1 plan, suggesting it was not based on immediate, non-public information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake.

Future Outlook

NA

Industry Context

This is a routine insider transaction for a director of a pharmaceutical company. It does not inherently reflect broader industry trends, but rather individual compensation and portfolio management.

Comparison to Industry Standards

• Insider transactions, particularly those involving option exercises and sales, are common across all industries, including pharmaceuticals, as part of executive compensation and personal financial planning.
• The use of a Rule 10b5-1 plan is standard practice for insiders to manage their equity holdings while avoiding accusations of trading on material non-public information.

Related Party Transactions

• Director Saira Ramasastry, a related party, engaged in the exercise of stock options and subsequent sale of common stock.

Stakeholder Impact

• Shareholders: May view the sale as a slight negative due to reduced insider ownership, but the 10b5-1 plan mitigates concerns about opportunistic selling. The significant profit realized by the director could be seen as a positive reflection of stock performance.
• Employees: No direct impact.
• Management: No direct impact beyond the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction where a director exercised options and sold an equivalent number of shares. While the sale reduces the director's direct equity stake, it was executed under a 10b5-1 plan, which suggests it was not based on new, material non-public information. The transaction itself does not provide new fundamental information about the company's operations, financial health, or future prospects that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, Saira Ramasastry, 10b5-1 Plan